ÓSKARE CAPITAL QUARTERLY NEWSLETTER
APRIL 2021
Read more
Media
- News
- Insights
- Media contact details
News
Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS
ÓSKARE Fund I & Medical Cannabinoids
Read moreÓSKARE CAPITAL STRENGTHENS TEAM AND EXTENDS COVERAGE TO THE AMERICAS BY WELCOMING JD WECHSLER AS VENTURE PARTNER
As we prepare for our first closing in Q1 2021, Óskare Capital is pleased to announce that JD Wechsler will…
Read moreÓSKARE CAPITAL STRENGTHENS TEAM WITH TWO NEW MEMBERS
Óskare Capital is pleased to announce that Oliver Lamb will be joining as Co-Founder and Investment Manager in the investment…
Read moreBroughton bids farewell to Mercia
Mercia Asset Management has lost its investment director and university lead Nicola Broughton to a new $171m fund targeting the…
Read moreCentral Bank signs off on €150m legal cannabis fund
THE Central Bank of Ireland has given the green light for an Irish domiciled investment fund that is seeking to…
Read moreMedical cannabis private equity fund established
Ireland's first ever private equity medical cannabis fund has been established. The new venture has been set up by Crossroads…
Read moreCannabis thérapeutique : un fonds veut doper l’écosystème européen
Oskare Capital lance Oskare Fund I, un fonds d'investissement qui va cibler des sociétés européennes développant des thérapies à base…
Read moreOctarine receives funding to develop biosynthetic platform for cannabinoid and psilocybin derivatives
Octarine Bio IVS (“Octarine” or the “Company”), a synthetic biology company developing functionally superior cannabinoid and psilocybin derivatives using microbial…
Read moreInsights
Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS
ÓSKARE Fund I & Medical Cannabinoids
Read moreThe Medical Cannabis Opportunity in the EU Stimulus Package
The good news for Europe’s Medical Cannabis industry is that, although not specifically named, the sector has touch points in…
Read moreMedia contact details
Alexandre OUIMET STORRS
- phone : +33 (0) 6 68 29 57 94
- email: alex@oskarecapital.com
Nicola BROUGHTON
- email: nicola@oskarecapital.com